On this page
Nystatin
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Polyene Antifungal [EPC] | EPC | All 12 members |
| Polyenes [CS] | CS | All 13 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 207767-001 | NYSTATIN | OINTMENT | NYSTATIN | Prescription | AT |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Original application | 1 | Approved | May 25, 2018 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260508). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Nystatin Ointment, USP is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candidaspecies. Nystatin Ointment, USP is not indicated for systemic, oral, intravaginal or ophthalmic use.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Nystatin Ointment USP should be applied liberally to affected areas twice a day or as indicated until healing is complete. Nystatin cream is usually preferred to nystatin ointment in candidiasis involving intertriginous areas; very moist lesions, however, are best treated with nystatin topical powder. This preparation does not stain skin or mucous membranes and provides a simple, convenient means of treatment.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Nystatin ointment, USP is contraindicated in patients with a history of hypersensitivity to any of its components.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The frequency of adverse events reported in patients using Nystatin Ointment preparations is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application. (See PRECAUTIONS: General.) To report SUSPECTED ADVERSE REACTIONS, contact Macleods Pharma USA, Inc., at 1-888-943-3210 or 1-855-926-338 or FDA at 1-800-FDA-1088 ( www.fda.gov/medwatch ).
Description
openFDA Drug LabelingDESCRIPTION Nystatin Ointment, USP is for dermatologic use. Nystatin Ointment, USP for topical use only, contains 100,000 USP nystatin units per gram, in a white petrolatum base. Nystatin is a polyene antifungal antibiotic drug obtained from Streptomyces nursei . The structural formula is as follows: Molecular Weight 926.13 Molecular Formula C 47 H 75 NO 17 image description
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Nystatin ointment USP, 100,000 units per gram is a pale yellow to yellow color ointment available as follows: NDC 13668-534-01 15 gram tube NDC 13668-534-02 30 gram tube STORAGE Store at 20° to 25°C (68° to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Manufactured by: Torrent Pharmaceuticals LTD., Pithampur-454775, INDIA . Manufactured for: Torrent Pharma INC., Basking Ridge, NJ 07920 8102492 Revised: March 2026 Image
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: NYSTATIN. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 50090-5845-0 | 50090-5845 | A-S Medication Solutions | 15 g in 1 TUBE (50090-5845-0) | November 4, 2021 |
| 0472-0166-15 | 0472-0166 | Actavis Pharma, Inc. | 1 TUBE in 1 CARTON (0472-0166-15) / 15 g in 1 TUBE | September 3, 2002 |
| 0472-0166-30 | 0472-0166 | Actavis Pharma, Inc. | 1 TUBE in 1 CARTON (0472-0166-30) / 30 g in 1 TUBE | September 3, 2002 |
| 63629-2515-1 | 63629-2515 | Bryant Ranch Prepack | 30 g in 1 TUBE (63629-2515-1) | May 18, 2021 |
| 63629-2516-1 | 63629-2516 | Bryant Ranch Prepack | 15 g in 1 TUBE (63629-2516-1) | May 18, 2021 |
| 72162-2007-2 | 72162-2007 | Bryant Ranch Prepack | 15 g in 1 TUBE (72162-2007-2) | February 6, 2024 |
| 72162-2007-3 | 72162-2007 | Bryant Ranch Prepack | 30 g in 1 TUBE (72162-2007-3) | February 6, 2024 |
| 72162-2333-2 | 72162-2333 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-2333-2) / 15 g in 1 TUBE | June 18, 2024 |
| 72162-2333-3 | 72162-2333 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-2333-3) / 30 g in 1 TUBE | June 18, 2024 |
| 0713-0686-15 | 0713-0686 | Cosette Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (0713-0686-15) / 15 g in 1 TUBE | July 30, 2018 |
| 0713-0686-31 | 0713-0686 | Cosette Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (0713-0686-31) / 30 g in 1 TUBE | July 30, 2018 |
| 69315-307-15 | 69315-307 | Leading Pharma, LLC | 1 TUBE in 1 CARTON (69315-307-15) / 15 g in 1 TUBE | August 19, 2019 |
| 69315-307-30 | 69315-307 | Leading Pharma, LLC | 1 TUBE in 1 CARTON (69315-307-30) / 30 g in 1 TUBE | August 19, 2019 |
| 33342-481-15 | 33342-481 | Macleods Pharmaceuticals Limited | 1 TUBE in 1 CARTON (33342-481-15) / 15 g in 1 TUBE | January 29, 2021 |
| 33342-481-30 | 33342-481 | Macleods Pharmaceuticals Limited | 1 TUBE in 1 CARTON (33342-481-30) / 30 g in 1 TUBE | January 29, 2021 |
| 45802-048-11 | 45802-048 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-048-11) / 30 g in 1 TUBE | November 8, 2006 |
| 45802-048-35 | 45802-048 | Padagis Israel Pharmaceuticals Ltd | 1 TUBE in 1 CARTON (45802-048-35) / 15 g in 1 TUBE | September 15, 2006 |
| 63187-464-15 | 63187-464 | Proficient Rx LP | 1 TUBE in 1 CARTON (63187-464-15) / 15 g in 1 TUBE | January 1, 2019 |
| 71205-437-15 | 71205-437 | Proficient Rx LP | 1 TUBE in 1 CARTON (71205-437-15) / 15 g in 1 TUBE | March 19, 2020 |
| 13668-534-01 | 13668-534 | Torrent Pharmaceuticals Limited | 15 g in 1 TUBE (13668-534-01) | January 29, 2019 |
| 13668-534-02 | 13668-534 | Torrent Pharmaceuticals Limited | 30 g in 1 TUBE (13668-534-02) | January 29, 2019 |
| 72578-089-01 | 72578-089 | Viona Pharmaceuticals Inc | 15 g in 1 TUBE (72578-089-01) | June 24, 2020 |
| 72578-089-04 | 72578-089 | Viona Pharmaceuticals Inc | 30 g in 1 TUBE (72578-089-04) | June 24, 2020 |
| 70771-1357-1 | 70771-1357 | Zydus Lifesciences Limited | 15 g in 1 TUBE (70771-1357-1) | August 8, 2018 |
| 70771-1357-2 | 70771-1357 | Zydus Lifesciences Limited | 30 g in 1 TUBE (70771-1357-2) | August 8, 2018 |
| 50090-5845 | 50090-5845 | A-S Medication Solutions | — | June 24, 2020 |
| 0472-0166 | 0472-0166 | Actavis Pharma, Inc. | — | September 3, 2002 |
| 63629-2515 | 63629-2515 | Bryant Ranch Prepack | — | June 24, 2020 |
| 63629-2516 | 63629-2516 | Bryant Ranch Prepack | — | June 24, 2020 |
| 72162-2007 | 72162-2007 | Bryant Ranch Prepack | — | June 24, 2020 |
| 72162-2333 | 72162-2333 | Bryant Ranch Prepack | — | September 15, 2006 |
| 0713-0686 | 0713-0686 | Cosette Pharmaceuticals, Inc. | — | October 6, 2017 |
| 69315-307 | 69315-307 | Leading Pharma, LLC | — | August 19, 2019 |
| 33342-481 | 33342-481 | Macleods Pharmaceuticals Limited | — | January 29, 2021 |
| 45802-048 | 45802-048 | Padagis Israel Pharmaceuticals Ltd | — | September 15, 2006 |
| 63187-464 | 63187-464 | Proficient Rx LP | — | September 3, 2002 |
| 71205-437 | 71205-437 | Proficient Rx LP | — | October 6, 2017 |
| 13668-534 | 13668-534 | Torrent Pharmaceuticals Limited | — | January 29, 2019 |
| 72578-089 | 72578-089 | Viona Pharmaceuticals Inc | — | June 24, 2020 |
| 70771-1357 | 70771-1357 | Zydus Lifesciences Limited | — | August 8, 2018 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.